This exploratory study suggests that imeglimin may improve liver enzyme levels and the Fib-4 index in individuals with type 2 diabetes who exhibit elevated ALT levels (≥ 25 IU/L), potentially indicating coexisting MASLD. The gene discussed is GPT; the disease is type 2 diabetes mellitus.